Enhancing Patient Privacy in Dermatology: Best Practices for Image Organization and Security [0.03%]
皮肤病学中改善患者隐私：图片组织和安全的最佳做法
Ryan Koch,Kritin K Verma,Sino Mehrmal et al.
Ryan Koch et al.
Christine Olagun-Samuel,Edwine Coulanges,Aminat Ologunebi et al.
Christine Olagun-Samuel et al.
Clinical Efficacy of Second-Generation Tetracyclines as First-Line Systemic Agents for Gingival Lichen Planus [0.03%]
二代四环素类药物作为天疱疮扁平苔藓的首选全身用药的临床疗效研究
Drore Eisen
Drore Eisen
Background: Oral lichen planus (OLP) patients with erythematous or erosive gingival lesions frequently fail topical therapy. The aim of this study was to determine the efficacy of minocycline and doxycycline for inflammat...
Racial Disparities in United States Clinical Trial Enrollment for Mycosis Fungoides and Sézary Syndrome [0.03%]
皮炎型淋巴瘤和塞扎里综合征临床试验中美籍不同族裔的差异性
Richard Rookwood,Nicole Schiraldi,Janet Choi et al.
Richard Rookwood et al.
Background: Racial disparities in clinical trial enrollment can limit the generalizability of therapeutic data, which is particularly damaging for conditions that disproportionately impact minority patients, such as mycos...
Dual IL-17A/F Blockade for Acrodermatitis Continua of Hallopeau: A Clinical Response to Bimekizumab [0.03%]
用于治疗豪洛佩恩连续性肢端皮炎的双效IL-17A/F阻断疗法：Bimekizumab临床疗效观察
Bradley Boman,Andy Rackham,David Cotter
Bradley Boman
Acrodermatitis continua of Hallopeau (ACH) is a rare, localized variant of pustular psoriasis that primarily affects the distal digits and nail apparatus, often presenting with recurrent pustules, nail dystrophy, and significant functional ...
Amelioration of Dominant Dystrophic Epidermolysis Bullosa Ulceration by Combination Gentian Violet and Trichloroacetic Acid Therapy [0.03%]
番木瓜与紫草素联合治疗营养不良性大疱表皮松解症溃疡疗效观察
Christina Huang,Rakan Radi,Jack L Arbiser
Christina Huang
Introduction: Dominant dystrophic epidermolysis bullosa (DDEB) is a hereditary genetic disorder with a mutation of the type VII collagen gene (COL7A1), leading to a destabilized dermal-epidermal junction. Current treatmen...
Prevalence of Pruritus in Type 2 Diabetic Patients on GLP-1 Agonist Therapy [0.03%]
利拉鲁肽治疗的2型糖尿病患者皮肤瘙痒患病率及其影响因素分析
Dennis Chu,Matthew Chen,James Briley et al.
Dennis Chu et al.
Prospective Single-Site Open-label Study Assessing Safety and Efficacy of Poly-L-Lactic Acid for Temple Volume Loss [0.03%]
聚乳酸注射填充剂治疗太阳穴容量丢失的单部位开放标记研究：安全性和有效性评估
Suleima Arruda,Alyssa Swearingen,Zahya Elmadany et al.
Suleima Arruda et al.
Background: Poly-l-lactic acid (PLLA) is an injectable biostimulatory filler used for restoring facial fat volume loss. Objective: To e...
A Novel Topical Agent for the Management of Hyperpigmentation, Including Melasma and Age Spots [0.03%]
用于治疗色素沉着过度（包括黄褐斑和老年斑）的新型外用药物
Xinge Diana Zhang,Claudia Teng,Xuefei Bai et al.
Xinge Diana Zhang et al.
Background/objectives: Melasma and age spots are among the most persistent and difficult-to-treat forms of hyperpigmentation. While traditional therapies offer some clinical efficacy, they often carry risks of irritation ...
Characterizing Safety Outcomes of a Dermal Filler: Injection Site and Timing Insights from the Maude Database [0.03%]
注射部位和时间对皮肤填充剂安全性的影响——来自Maude数据库的见解
Mark Spivak,Esther Auerbach,Elana Eisenreich et al.
Mark Spivak et al.
Background: Juvéderm Volbella distinguishes itself for being the only hyaluronic acid filler with dual FDA approval for perioral and infraorbital regions. Its Vycross technology formulation and use in high-risk vas...